Jordan vs Latin America and the Caribbean: Percentage of bloodstream infection due to Escherichia coli resistant
Jordan
57.2%
in 2022
Latin America and the Caribbean
30.9%
in 2022
Jordan rank
15th
Latin America and the Caribbean rank
13th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Jordan
- Latin America and the Caribbean
How they compare
Jordan currently reports 57.2% against 30.9% in Latin America and the Caribbean, a difference of 26.3%.
That makes Jordan's figure about 1.8 times Latin America and the Caribbean's.
Across all 5 years both countries report, Jordan has been ahead every year.
Jordan ranks 15th and Latin America and the Caribbean ranks 13th of 50 countries.
Jordan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Jordan | Latin America and the Caribbean | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 64.3% | 20.2% | 44.1% | Jordan |
| 2020s | 60.7% | 28.3% | 32.4% | Jordan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Jordan or Latin America and the Caribbean?
- Jordan, at 57.2% against 30.9% in Latin America and the Caribbean as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Jordan and Latin America and the Caribbean?
- 26.3%, with Jordan ahead.
- How many years of comparable data are there for Jordan and Latin America and the Caribbean?
- 5 years are reported by both, from 2018 to 2022.
- How do Jordan and Latin America and the Caribbean rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Jordan ranks 15th and Latin America and the Caribbean ranks 13th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.